BLAINJECTIONINJECTABLEPriority Review
Approved
Nov 2022
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
11
Data completeness
4/8 — Partial
Priority Review
ELAHERE (mirvetuximab soravtansine) by AbbVie is soravtansine-gynx is an antibody-drug conjugate (adc). First approved in 2022.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ELAHERE (mirvetuximab soravtansine) is an antibody-drug conjugate (ADC) that targets folate receptor alpha (FRα) and delivers a microtubule-disrupting payload (DM4) directly to cancer cells. Upon binding to FRα-expressing cells, the drug is internalized and releases DM4, which arrests the cell cycle and triggers apoptosis. It is indicated for FRα-positive epithelial ovarian cancer and related tumors.
Peak
Product is in peak commercial phase with moderate competitive pressure (30/100); expect stable team size and focus on market penetration and reimbursement strategies.
Mechanism of Action
soravtansine-gynx is an antibody-drug conjugate (ADC). The antibody is a chimeric IgG1 directed against folate receptor alpha (FRα). The small molecule, DM4, is a microtubule inhibitor attached to the antibody via a cleavable linker. Upon binding to FRα, mirvetuximab soravtansine-gynx is…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (11)
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
Started Dec 2025
1,100 enrolled
Epithelial Ovarian Cancer
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Started Nov 2025
140 enrolled
Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer+1 more
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
Started Nov 2025
400 enrolled
Ovarian Cancer
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
Started May 2025
110 enrolled
Advanced High-Grade Epithelial Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancers
A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
Started Jul 2024
100 enrolled
Recurrent Ovarian CancerFolate Receptor-Alpha Positive
Worked on ELAHERE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.